---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-294930"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T13:13:40.120215+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Pfizer completes $43B acquisition of Seagen at $229/share, expanding oncology portfolio

## Summary
- Pfizer acquired Seagen for $229 per share in cash, total enterprise value of ~$43 billion.
- Acquisition adds Seagen's four in-line ADC medicines (ADCETRIS, PADCEV, TIVDAK, TUKYSA) to Pfizer's oncology portfolio.
- Pfizer's oncology pipeline doubles to 60 programs; now includes over 25 approved medicines across more than 40 indications.
- To address FTC concerns, Pfizer irrevocably donates U.S. royalties from Bavencio (avelumab) to American Association for Cancer Research.
- Pfizer expects oncology to be a significant growth driver and contribute to near- and long-term financial goals.

## SEC filing metadata
- accession: 0001193125-23-294930
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000119312523294930/0001193125-23-294930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000119312523294930/d553734d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-294930
- JSON: https://secwatch.observer/filing/0001193125-23-294930.json
- Plain text: https://secwatch.observer/filing/0001193125-23-294930.txt

## Key facts
- M&A Transactions
  PFIZER INC completed an acquisition involving Seagen Inc. for $229.00 in cash per share, for a total enterprise value of approximately $43 billion (closed 2023-12-14).
  - Action: acquisition
  - Counterparty: Seagen Inc.
  - Consideration: $229.00 in cash per share, for a total enterprise value of approximately $43 billion
  - Closing: 2023-12-14
  source text: Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000119312523294930/0001193125-23-294930-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.